Clinical Trial Update: A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a combination of sasanlimab, palbociclib, and axitinib in metastatic renal cell carcinoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma
• Translocation Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)
• Palbociclib (palbociclib)
• Sasanlimab (sasanlimab)

Snippet

Sponsor: Stephanie Berg | Conditions: Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer | Phase 2 | Status: RECRUITING